© 1996 AlphaMed Press
Biochemical and Molecular Studies of Human Methenyltetrahydrofolate SynthetaseCentre de Recherche, Hôtel-Dieu de Montréal, Montréal, Québec, Canada Correspondence: Jacques Jolivet, M.D., Centre de Recherche, Hôtel-Dieu de Montréal, 3850 rue Saint-Urbain, Montréal, Québec, H2W 1T8, Canada. Telephone: 514-843-2700; Fax: 514-843-2715; e-mail: jolivetj{at}ERE.UMontreal.CA
5-FormylH4folate is administered clinically under the name LeucovorinTM in association with the antineoplastic agent 5-fluorouracil (5-FU) to enhance the cytotoxic effects of 5-FU. The combination has been shown to be superior to 5-FU alone in the treatment of patients with metastatic colorectal carcinoma. Methenyltetrahydrofolate synthetase (MTHFS) catalyzes the transformation of 5-formyltetrahydrofolate to methenylH4folate, which is the obligatory initial metabolic step prior to the intracellular conversion of 5-formylH4folate to other reduced folates and the increase in intracellular folate pools required for 5-FU potentiation. In the following paper, we will summarize results of biochemical and molecular studies of human MTHFS.
This article has been cited by other articles:
Copyright © 1996 by AlphaMed Press. |
||||||||||||||||||||||||||||||||